Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.
Matt Cooper, PhD
Advertisement
Executive Director and Therapeutic Strategy Lead, Oncology, at Worldwide Clinical Trials
Articles by Matt Cooper, PhD
Advertisement
Latest Updated Articles
Revolutionizing Oncology: Insights on the FDA’s Project Optimus and Dose OptimizationPublished: September 20th 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
Overcoming Recruitment and Retention Barriers in Alzheimer’s and Dementia Studies
3
Focusing on Site Needs and Challenges: Quick Tips for Sponsors/CROs
4
Balancing Human Oversight and Automation in AI-Driven Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
